121 patents
Page 5 of 7
Utility
Optimizing Mifepristone Absorption
18 Feb 21
The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration.
Joe Belanoff, Robert Roe, Caroline Loewy
Filed: 3 Nov 20
Utility
Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer
4 Feb 21
Hazel Hunt, Thaddeus S. Block
Filed: 21 Oct 20
Utility
Glucocorticoid receptor modulators to treat cervical cancer
26 Jan 21
Methods for treating a subject having a cancerous tumor are disclosed.
Hazel Hunt
Filed: 14 Jan 20
Utility
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
4 Jan 21
The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
Joseph K. Belanoff, Hazel Hunt, Onno C. Meijer, José van den Heuvel
Filed: 23 Jan 19
Utility
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
23 Nov 20
Joseph K. Belanoff
Filed: 12 Dec 18
Utility
Optimizing mifepristone absorption
23 Nov 20
The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration.
Joe Belanoff, Robert Roe, Caroline Loewy
Filed: 17 Sep 19
Utility
Use of Cortisol In Assessment and Prophylactic Treatment of Hypokalemia Associated with Glucocorticoid Receptor Modulator Treatment of Cushing's Syndrome Patients
18 Nov 20
This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia.
Andreas Moraitis
Filed: 30 Jul 20
Utility
Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators
18 Nov 20
The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
Hazel Hunt, Iain Walters, Benoit Gourdet
Filed: 3 Aug 20
Utility
Glucocorticoid receptor modulators to treat pancreatic cancer
9 Nov 20
Hazel Hunt, Thaddeus S. Block
Filed: 7 Apr 20
Utility
Octahydro fused azadecalin glucocorticoid receptor modulators
28 Sep 20
The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
Hazel Hunt, Iain Walters, Benoit Gourdet
Filed: 11 Apr 19
Utility
Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
21 Sep 20
This invention provides new methods for a) identifying Cushing's Syndrome patients at high risk of developing hypokalemia during glucocorticoid receptor modulator (GRM) treatment, and b) for prophylactically treating such patients to prevent, or reduce the severity of, hypokalemia.
Andreas Moraitis
Filed: 21 Aug 18
Utility
Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator
26 Aug 20
Andreas Moraitis
Filed: 20 Feb 20
Utility
Optimizing Mifepristone Levels for Cushing's Patients
19 Aug 20
The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome.
Joseph Belanoff, Coleman Gross
Filed: 4 May 20
Utility
Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer
22 Jul 20
Hazel Hunt, Thaddeus S. Block
Filed: 7 Apr 20
Utility
Methods for Diagnosing and Assessing Treatment for Cushing's Syndrome
8 Jul 20
Methods are provided for assessing a clinical response to a glucocorticoid receptor antagonist (GRA) in a human subject and for diagnosing Cushing's syndrome.
Joseph K. Belanoff, Hazel Hunt, John Francis Unitt, Andreas G. Moraitis
Filed: 18 Mar 20
Utility
Use of Glucocorticoid Receptor Antagonists In Combination with Glucocorticoids to Treat Adrenal Insufficiency
1 Jul 20
This invention provides for a method of h eating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof.
Andreas G. MORAITIS, Pejman COHAN, Joseph K. BELANOFF
Filed: 10 Mar 20
Utility
Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound
24 Jun 20
Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs).
Ian Scott, Travis Lemons, Yan Alsmeyer, Yip-Fong Chia, Stephen Arboleda
Filed: 17 Dec 19
Utility
Methods of Treating Cancer Comprising Administration of a Glucocorticoid Receptor Modulator and a Cancer Chemotherapy Agent
24 Jun 20
Andrew Greenstein, Stacie Shepherd, Andreas G. Moraitis
Filed: 17 Dec 19
Utility
Methods of Treating Cancer Comprising Administration of a Glucocorticoid Receptor Modulator and a Cancer Chemotherapy Agent
24 Jun 20
Andrew Greenstein, Stacie Shepherd, Andreas G. Moraitis
Filed: 16 Jan 20
Utility
Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators
24 Jun 20
Andreas G. Moraitis
Filed: 19 Dec 19